Breast cancer drug may be 'too expensive'
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.A senior member of the Government's medicines watchdog has warned that the breast cancer drug Herceptin may be unaffordable by the NHS.
The drug was granted a licence for use in early breast cancer by the European Medicines Agency yesterday, presenting NHS trusts with the dilemma of whether to fund it.
The licence was granted in 53 days, the quickest it has ever happened, after the agency agreed to speed up its process in response to public and political demand for the drug.
Professor Ian Smith, head of the breast cancer unit at the Royal Marsden Hospital, London, said: "For women with HER2-positive breast cancer, Herceptin is one of the most important developments we have ever seen, so the licence is excellent news for these women throughout the UK."
But the cost of the drug has alarmed holders of the NHS's purse strings, who have to balance competing budget demands.
Herceptin is being assessed by the National Institute for Health and Clinical Excellence (Nice), the Government body which decides which drugs should be recommended for use on the NHS on the basis of their cost effectiveness. A decision is expected "in a matter of weeks", Andrew Dillon, the chief executive of Nice, said yesterday.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments